PRECISION BIOSCIENCES INC (DTIL) stock intrinsic value fair value estimate & owner earnings analysis

Precision BioSciences is a clinical-stage gene editing company built around ARCUS, its proprietary genome editing enzyme. It has no approved products. Its two wholly owned programs are PBGENE-HBV, a potential cure for chronic hepatitis B now in the Phase 1/2a ELIMINATE-B trial (sites in Hong Kong, New Zealand, the United States and Moldova), and PBGENE-DMD for Duchenne muscular dystrophy, which received FDA clearance in February 2026 to start the FUNCTION-DMD Phase 1/2 trial, with first patient data expected by year-end 2026. A third program, PBGENE-3243, has been paused. The company also holds economics in programs run by others: azer-cel, licensed to Imugene for lymphoma (up to $206 million in milestones, of which $8 million was received in October 2025, plus double-digit royalties) and to TG Therapeutics for multiple sclerosis (a $7.5 million milestone earned in March 2026 and up to $288.6 million more), and an ARCUS-based therapy for neonatal OTC deficiency being tested by iECURE in a study that could support approval. What the business has actually earned. Revenue has come entirely from partners, not from selling medicines. The large partnerships that once funded the company have ended: Novartis concluded in 2025 and Prevail (Eli Lilly) in 2024. On an owner-earnings basis (operating cash flow, less stock-based pay, less capital spending, with timing swings in working capital removed) the company lost money in every year from 2018 through 2025, about $617 million in total. One accounting judgement matters here: when a partner pays up front, the company books that money as revenue slowly over several years. We count the cash in the year it actually arrived and do not count the later bookkeeping revenue again, because by then the cash is already gone. On that basis the business consumed $99.5 million in 2023, $75.9 million in 2024 and $73.1 million in 2025. Our starting point is the median of those three years, about $76 million a year, measured from the 2023 exit from its earlier cell therapy business onward, since the years before describe a different company. Per-share figures in the history are not meaningful because the share count grew roughly 25-fold, adjusted for the 1-for-30 reverse split in February 2024. Near-term path. Losses shrank by about 4% from 2024 to 2025. We assume the gap narrows faster, to about $62 million in 2027 after partner payments, because spending has already come down: operating expenses were $39.0 million in the first half of 2026 against $44.0 million a year earlier, and the paused PBGENE-3243 program cuts costs further. Even so, the second quarter of 2026 ran at about $19 million of operating expense with no revenue, which is a rate of roughly $77 million a year. Balance sheet. At June 30, 2026 the company held $86.1 million of unrestricted cash, plus $26.3 million of restricted cash, most of which is pledged against a $22.5 million Banc of California term loan, so the loan is effectively covered. A $36.7 million warrant liability on the balance sheet is an accounting measure of warrants to acquire shares at $7.25; it is not cash owed. Management says its cash, the expected azer-cel milestone and its at-the-market share sales program will fund operations through 2028. That plan depends on selling new shares, which dilutes today's owners. We count about 29 million shares including pre-funded warrants. The cases. Value here comes down to how much of today's cash is spent before something can be sold or licensed, and what it fetches. The company's record gives the range: Servier paid $105 million up front in 2016, Lilly paid $100 million plus a $35 million share purchase in 2021, Novartis paid $50 million up front plus a share purchase in 2022, and TG Therapeutics paid $10 million in 2024. Partner cash over the last three years has run at about $8 million a year. Bear case, $0.00 per share. The hepatitis B and Duchenne readouts in 2026-2027 do not support moving forward. The company keeps spending at close to today's rate through 2027, uses up its unrestricted cash and then winds down. Partner milestones dry up. The loan is repaid from its pledged cash, so there is no shortfall to creditors, but nothing is left for shareholders. Base case, $0.41 per share. The company carries out its plan through 2028, spending about $35 million in the rest of 2026, $70 million in 2027 and $65 million in 2028. It collects about $8 million a year from the azer-cel partners, in line with its recent record. PBGENE-HBV moves into the expansion part of its trial and is partnered in 2028 for about $60 million up front plus about $20 million in later milestones, near the middle of the company's own past deals. We give PBGENE-DMD no value, because it has no human data yet. After 2028 the programs run on partner money and we assume nothing beyond that. Most of today's cash is spent getting there, which is why the base value is far below cash per share of about $3. Bull case, $5.97 per share. The hepatitis B trial finds a dose that allows patients to stop their existing antiviral drugs. That supports a partnership in 2027 on the scale of the 2021 Lilly deal (about $135 million up front) plus about $50 million in later milestones. Positive early Duchenne data leads to a second deal of about $50 million in 2028. TG Therapeutics' multiple sclerosis data and Imugene's move into a pivotal lymphoma study bring about $40 million in milestones. The $7.25 warrants are exercised, bringing in about $44 million for about 6 million new shares. We did not include royalties on eventual product sales in any case, because no program is near approval and none has shown it can produce sales. What would make this wrong. The value depends almost entirely on the hepatitis B and Duchenne data over the next 18 months and on whether management keeps spending if that data is weak. A deep partnership signed soon would move the value toward the bull case. Continued spending at the second-quarter 2026 rate with no deal would move it toward the bear case. We could not find the financial terms of the iECURE arrangement in the annual report, so it carries no separate value beyond the small iECURE stake the company holds. For years before 2024 we measured working capital from receivables and payables only; this does not change the conclusion, because the business lost money in every year. Margin-of-safety price. The bear case is a total loss and the outcome hinges on binary clinical data, so the margin-of-safety price sits very far below the base value, about 55% lower.